These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 378488

  • 21. [Control by means of Computer control of the hematochemical picture in chronic uremic patients undergoing periodic hemodialysis treatment].
    Novario PG, Pagliano B, Denti E, Segoloni G, Piccoli G, Vercellone A, Coppo R.
    Minerva Nefrol; 1974; 21(5):347-59. PubMed ID: 4467056
    [No Abstract] [Full Text] [Related]

  • 22. [Programmed use of hemoperfusion through activated charcoal in treatment of patients with terminal uremia].
    Levitskiĭ ER, Dmitriev AA, Pliaskina AV.
    Ter Arkh; 1977; 49(7):61-4. PubMed ID: 898078
    [No Abstract] [Full Text] [Related]

  • 23. Combined hemodialysis-hemoperfusion treatment reduces the time of substitutive therapy in chronic uremia.
    Stefoni S, Feliciangeli G, Coli L, Scolari MP, Bonomini V.
    Int J Artif Organs; 1981 Jul; 4(4):186-91. PubMed ID: 7327760
    [Abstract] [Full Text] [Related]

  • 24. Activated carbon fibers for hemoperfusion.
    Davis TA, Cowsar DR, Harrison SD, Tanquary AC.
    Trans Am Soc Artif Intern Organs; 1974 Jul; 20A():353-6. PubMed ID: 4450357
    [No Abstract] [Full Text] [Related]

  • 25. [Hemosorption in the therapeutic complex for renal insufficiency in children].
    Isakov IuF, Burkov IV, Drozdov VA, Mosharov OP, Osipov IuN.
    Urol Nefrol (Mosk); 1980 Jul; (5):55-9. PubMed ID: 7423691
    [No Abstract] [Full Text] [Related]

  • 26. Predialysis BUN and creatinine do not predict adequate dialysis, clinical rehabilitation, or longevity.
    Avram MM, Slater PA, Gan A, Iancu M, Pahilan AN, Okanya D, Rajpal K, Paik SK, Zouabi M, Fein PA.
    Kidney Int Suppl; 1985 Dec; 17():S100-4. PubMed ID: 3867776
    [No Abstract] [Full Text] [Related]

  • 27. [Treatment of chronic uremia with albumin/collodion-coated activated charcoal--A preliminary report].
    Amdahl T, Peterson JO.
    Lakartidningen; 1975 Feb 12; 72(7):587-8. PubMed ID: 1113574
    [No Abstract] [Full Text] [Related]

  • 28. A perspective on uremic toxins.
    Black DA.
    Arch Intern Med; 1970 Nov 12; 126(5):906-9. PubMed ID: 5475716
    [No Abstract] [Full Text] [Related]

  • 29. Comparative studies on the effect of hemoperfusion and hemodialysis on the elimination of some uremic toxins.
    Trznadel K, Walasek L, Kidawa Z, Lutz W.
    Clin Nephrol; 1978 Dec 12; 10(6):229-31. PubMed ID: 729215
    [Abstract] [Full Text] [Related]

  • 30. Improvement of continuous arteriovenous hemofiltration (CAVH) and hemofiltration (HF) efficiency by adding hemoperfusion (HP).
    Marangoni R, Civardi F, Masi F, Avanzi C, Savino R, Manfredi A, Cimino R.
    Biomater Artif Cells Artif Organs; 1990 Dec 12; 18(4):541-8. PubMed ID: 2285819
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Hemoperfusion in the treatment of endogenous and exogenous poisoning].
    Trznadel K.
    Pol Tyg Lek; 1978 Jan 30; 33(5):203-5. PubMed ID: 652646
    [No Abstract] [Full Text] [Related]

  • 33. Identification of metabolites and their chemical removal from blood in renal failure.
    Bultitude FW.
    Biomed Eng; 1970 May 30; 5(5):240-3. PubMed ID: 5422363
    [No Abstract] [Full Text] [Related]

  • 34. Microcapsule artificial kidney and medium molecular weight clearance.
    Chang TM.
    Proc Eur Dial Transplant Assoc; 1972 May 30; 9():568-74. PubMed ID: 4668931
    [No Abstract] [Full Text] [Related]

  • 35. Clinical evaluation of chronic, intermittent, and short term hemoperfusions in patients with chronic renal failure using semipermeable microcapsules (artificial cells) formed from membrane-coated activated charcoal.
    Chang TM, Gonda A, Dirks JH, Malave N.
    Trans Am Soc Artif Intern Organs; 1971 May 30; 17():246-52. PubMed ID: 5158100
    [No Abstract] [Full Text] [Related]

  • 36. [Effect of hemoperfusion on various blood coagulation and fibrinolysis factors in chronic uremia].
    Lewicki R, Trznadel K, Luciak M, Kidawa Z.
    Pol Tyg Lek; 1981 Aug 31; 36(35):1325-7. PubMed ID: 7329845
    [No Abstract] [Full Text] [Related]

  • 37. Hemoperfusion for uremia: past, present, and future.
    Winchester JF, Ash SR.
    Kidney Int Suppl; 1985 Dec 31; 17():S127-30. PubMed ID: 3867782
    [No Abstract] [Full Text] [Related]

  • 38. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
    Trznadel K, Kidawa Z, Walasek L, Lutz W.
    Pol Tyg Lek; 1978 Feb 13; 33(7):257-9. PubMed ID: 758030
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Evaluation of a new coated charcoal for hemoperfusion in uremia.
    Stefoni S, Feliciangeli G, Coli L, Bonomini V.
    Int J Artif Organs; 1979 Nov 13; 2(6):320-3. PubMed ID: 511374
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.